Down sydrome_DSC_0906

Down Syndrome Drug Trial starts in NSW today

Researchers from NeuRA have launched a clinical study that they hope will help to enhance cognition in people with Down syndrome (DS). The study is the first of its kind to target cognitive enhancement in people with the condition.

An ingredient used for decades to treat a variety of conditions, from respiratory ailments to senile dementia, could hold the key to improving memory, language, and learning in people with DS. Starting today, researchers will investigate the effectiveness of the ingredient, known as BTD-001.

Study leader Professor Rhoshel Lenroot from NeuRA says early scientific evidence on the drug’s ability to improve the cognitive function is promising. “For the first time, we are able to take what we have learned about brain differences in people with DS and use the information to develop new approaches to enhancing cognitive function.”
“We’re hopeful that this trial, and further development of the drug, leads to a product that could lessen some of the difficulties people with the condition may have – for example with learning at school or being able to live independently.”

Catherine McAlpine, CEO of Down Syndrome Australia, says, “We welcome all research that looks to improve the lives of people with DS and their families – research that is all too rare.”

“People with Down syndrome deserve the same opportunities as all other community members, and this includes research that aims to improve their lives.”
NeuRA is now recruiting people with Down syndrome aged between 13 and 35, and based in NSW, for the sixteen-week study.

Those wanting to participate should call 1300 659 729 or visit compose21.com for more detail.